# PureTech Health plc: overview PTCHF · OTC · CIK 1782999 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ptchf.md) · [Financials](/companies/ptchf/financials.md) · [Filings](/companies/ptchf/filings.md) · [Insiders](/companies/ptchf/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.8](/filings/0001782999-23-000004.md) | [17.4](/filings/0001628280-24-017913.md) | [15.6](/filings/0001782999-25-000005.md) | [3.3](/filings/0001782999-25-000005.md) | [4.8](/filings/0001782999-25-000005.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1015.7%)](/filings/0001782999-23-000004.md) | [(864.3%)](/filings/0001628280-24-017913.md) | [(1266.5%)](/filings/0001782999-25-000005.md) | [(4390.4%)](/filings/0001782999-25-000005.md) | [(2818.9%)](/filings/0001782999-25-000005.md) | | Net margin | % | [50.9%](/filings/0001782999-23-000004.md) | [(348.3%)](/filings/0001628280-24-017913.md) | [(322.4%)](/filings/0001782999-25-000005.md) | [(1972.9%)](/filings/0001782999-25-000005.md) | [1108.3%](/filings/0001782999-25-000005.md) | | Diluted EPS | $ per share | [0.02](/filings/0001782999-23-000004.md) | [(0.21)](/filings/0001628280-24-017913.md) | [(0.18)](/filings/0001782999-25-000005.md) | [(0.24)](/filings/0001782999-25-000005.md) | [0.21](/filings/0001782999-25-000005.md) | | Free cash flow | $m | [(137)](/filings/0001782999-23-000004.md) | [(164)](/filings/0001628280-24-017913.md) | [(181)](/filings/0001782999-25-000005.md) | [(106)](/filings/0001782999-25-000005.md) | [(134)](/filings/0001782999-25-000005.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ptchf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) None of the funds in coverage reports a position in its latest 13F. ## Recent filings [All 123 filings](/companies/ptchf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-05-01 | 08:05 ET | [6-K](/filings/0001193125-26-199177.md) | Report of a foreign private issuer, period 2026-05-01 | 0001193125-26-199177 | | 2026-04-29 | 10:46 ET | [20-F](/filings/0001628280-26-028200.md) | Annual report of a foreign private issuer, period 2025-12-31 | 0001628280-26-028200 | | 2026-04-29 | 06:08 ET | [6-K](/filings/0001193125-26-188811.md) | Report of a foreign private issuer, period 2026-04-29 | 0001193125-26-188811 | | 2026-04-29 | 06:05 ET | [6-K](/filings/0001193125-26-188793.md) | Report of a foreign private issuer, period 2026-04-29 | 0001193125-26-188793 | | 2025-12-18 | 07:00 ET | [6-K](/filings/0001193125-25-323679.md) | Report of a foreign private issuer, period 2025-12-18 | 0001193125-25-323679 | | 2025-12-10 | 16:30 ET | [6-K](/filings/0001193125-25-314304.md) | Report of a foreign private issuer, period 2025-12-10 | 0001193125-25-314304 | | 2025-08-28 | 06:47 ET | [6-K](/filings/0001628280-25-041238.md) | Report of a foreign private issuer, period 2025-06-30 | 0001628280-25-041238 | | 2025-07-16 | 06:30 ET | [6-K](/filings/0001193125-25-159538.md) | Report of a foreign private issuer, period 2025-07-16 | 0001193125-25-159538 | | 2025-07-08 | 16:15 ET | [6-K](/filings/0001193125-25-156607.md) | Report of a foreign private issuer, period 2025-07-08 | 0001193125-25-156607 | | 2025-06-16 | 16:30 ET | [6-K](/filings/0001193125-25-141445.md) | Report of a foreign private issuer, period 2025-06-16 | 0001193125-25-141445 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-028200.md), filed Apr 29, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1782999 - Tickers: PTCHF, PRTCY - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: X0 - Filer category: Accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.